RDT helps bring orphan drugs to market by partnering with companies to provide life-saving therapies for patients with rare diseases.
With over 30 years of experience in orphan drug commercialization, including experience in antivenoms, oncology, hematology, metabolic diseases, and genetic disorders, RDT maintains a foundational presence in rare disease outreach.
1. McKiernan PJ (2006). “Nitisinone in the treatment of hereditary tyrosinaemia type 1”. Drugs. 66 (6): 743–750.